|Description||Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is used in the treatment of adults with essential hypertension. It inhibited cell proliferation at concentrations as low as 1 μmol/l in aortic endothelial cells in vitro. It has antiproliferative effects of azilsartan were also observed in cells lacking AT1 receptors. It was developed by Takeda Corporation. It has been listed.|
|Appearance||White or white crystalline powder|
|Synonyms||1-[[2'-(2,5-Dihydro-5-oxo-1,2,4-oxadiazol-3-yl)[1,1'-biphenyl]-4-yl]methyl]-2-ethoxy-1H-benzimidazole-7-carboxylic acid (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl ester potassium salt;Azilsartan MedoxoMil PotassiuM salt;Azilsartan kamedoxomil;TAK 491 monopotassium;Potassium,(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-3-[[4-[2-(5-oxo-1-oxa-2-aza-4-azanidacyclopent-2-en-3-yl)phenyl]phenyl]methyl]benzimidazole-4-carboxylate|
|Solubility||10 mM in DMSO|
|Application||Azilsartan medoxomil monopotassium is used in the treatment of adults with essential hypertension.|
|Quality Standard||In-house standard|
|Shelf Life||2 month in rt, long time|
|Quantity||Kilogram to ton|
|Current Developer||Azilsartan medoxomil monopotassium was developed by Takeda Corporation. It has been listed.|
CGP-42112A, an angiotensin AT2 receptor agonist which could probably lead to the inhibition of ATPase and contraction of aortic rings in rabbit.
Angiotensin I/II (1-7)
Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor, inducing vasorelaxation through release of NO and prostaglandins.
AVE 0991 sodium salt
AVE 0991 sodium salt, is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.
Losartan Potassium (DuP 753)
Losartan is an angiotensin II receptor antagonist that competes with the binding of angiotensin II to AT1 receptors with IC50 of 20 nM. It promotes vasodilatati...
BMS 183920, a quinoline derivative, has been found to be an angiotensin II receptor antagonist that could have potential usage in antihypertensive study.
Cgp 48369 is a nonpeptide a angiotensin type 1 receptor antagonist originated by Novartis. Treatmenf for for Hypertension in Switzerland was discontinued in 199...
Tranilast, also called Rizaben or Tranilastum, has anti-inflammatory and immunomodulatory effect. It binds to Aβ40 monomers and increases Aβ40 fibrillation.
Candesartan blocks the effects of angiotensin II at the angiotensin II type 1 (AT1) receptor. Candesartan cilexetil is a prodrug that is activated to candesarta...
Azilsartan medoxomil monopotassium
Azilsartan medoxomil monopotassium is an azilsartan prodrug and and an orally administered angiotensin II receptor type 1 antagonist with IC50 of 0.62 nM. It is...
Olmesartan, a synthetic imidazole derivative, is a specific angiotensin II type 1 (AT1) receptor antagonist with antihypertensive effect. hAT1 receptors: IC50 =...
AVE 0991 is an agonist of nonpeptide Ang-(1-7) receptor Mas that has potential as a cardiovascular drug.
Olmesartan Medoxomil is a compound which is hydrolyzed to olmesartan that is a selective AT1 subtype angiotensin II receptor antagonist.
Telmisartan, also called Pritor, a benzimidazole derivative, is an angiotensin II receptor antagonist that can be used to treat hypertension. in vitro: activate...
Azilsartan Medoxomil is a potent angiotensin II type 1 (AT1) receptor antagonist that inhibits the RAAS, with an IC50 of 2.6 nM. It exhibits more than 10,000-fo...
An antagonist of Angiotensin type 1 receptor
Tranilast, an allergic media blocker, is effective for the treatment of asthma and is also used to treat asthma, allergic rhinitis and other allergic disorders.
Candesartan (10 mg/kg) inhibits the growth of engrafted tumors and reduces the microvessel density and VEGF expression in a mouse KU-19-19 xenograft model
BIBS 39, a nonpeptide angiotensin II receptor antagonist, has been found to exhibit potential antihypertensive activity in rat. It has been already discontinued...
An antagonist of angiotensin II receptor
Embusartan, an oxopyridine derivative, has been found to be an angiotensin II receptor antagonist that was once studied against hypertension by Bayer.